Cohance Lifesciences Ltd (COHANCE) is currently trading at 444.45 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Cohance Lifesciences is an integrated Indian CDMO providing custom synthesis, process R&D, scale‑up and contract manufacturing of intermediates, APIs, oligonucleotide building blocks, ADC payloads and formulations for global life sciences and fine chemical majors, having expanded through acquisitions such as Sapala and NJBio to offer multi‑modality capabilities from small molecules to nucleic acids. Q1 FY27 was a guided trough quarter with consolidated revenue of INR4,223 million and adjusted EBITDA of INR92 million; management expects sequential improvement from Q2 and year‑on‑year recovery by H2 FY27 driven by scheduled commercial deliveries, restocking orders and improved utilization across the platform as shipments phased into later quarters. Sapala showed rapid momentum, reporting 2.5x revenue growth as Sapala shipments for specialized nucleic acid building blocks commenced and amidites GMP operationalization progressed, prompting management to align an integrated nucleic acid business and target full ownership by FY30 as a strategic growth engine. NJ Bio remains a significant drag on consolidated profitability with an EBITDA loss driven by under‑utilization and higher US costs; Cohance intends to improve revenue conversion and utilization at NJ Bio while optimizing costs so that standalone operations and Sapala can demonstrate materially stronger margins. Cohance retains financial flexibility with consolidated net cash of approximately INR2,512 million at quarter end and is selectively investing in capability expansions such as flow reactors, effluent treatment, and nucleic acid facilities, while maintaining regulatory engagement after a recent USFDA inspection that resulted in a Form 483 with five observations.

Over the past 52 weeks, Cohance Lifesciences Ltd has traded between a low of ₹267.85 and a high of ₹778.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Cohance Lifesciences Ltd has a market capitalization of approximately 18,416.32. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Cohance Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 314.65 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 18,416.32 Cr, Cohance Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Cohance Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Cohance Lifesciences Ltd is 314.65. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Cohance Lifesciences Limited is the new identity of erstwhile Suven Pharmaceuticals Limited.

It announced US$10 million for a cGMP bioconjugation suite at NJ Bio (Princeton, US) and ₹230 million (₹23 crore) for a cGMP oligonucleotide building block facility in Hyderabad.

Biopharma Shakti is a new initiative with a ₹10,000 crore outlay over five years aimed at making India a global hub for biopharma manufacturing, focusing on biologics and biosimilars.